z-logo
Premium
Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus
Author(s) -
MillerLotan Rachel,
Herskowitz Yehuda,
KaletLitman Shiri,
Nakhoul Farid,
Aronson Doron,
Zoabi Roaa,
Asaf Roy,
BenIzhak Ofer,
Sabo Edmond,
Lim SaiKiang,
Baumann Heinz,
Berger Franklin G.,
Levy Andrew P.
Publication year - 2005
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.556
Subject(s) - medicine , endocrinology , allele , haptoglobin , diabetes mellitus , genotype , type 2 diabetes , renal hypertrophy , biology , muscle hypertrophy , diabetic nephropathy , gene , genetics
Background The human haptoglobin ( Hp ) gene is polymorphic with two functional classes of alleles, denoted 1 and 2. We have demonstrated in three longitudinal studies and several cross‐sectional studies that the Hp genotype is an independent risk factor for diabetic vascular disease. These studies have presented a compelling argument that diabetic individuals homozygous for the Hp 1 allele are at decreased risk of vascular complications as compared to diabetic individuals with the Hp 2 allele. Methods The naturally occurring (wild type) mouse Hp is a class 1 Hp allele. We examined renal hypertrophy in wild‐type mice, Hp knockout mice (Hp 0), and in mice with the Hp 2 allele (Hp 2) with and without diabetes. Results In the absence of diabetes, we found that renal hypertrophy was significantly increased in Hp 0 mice and that this could be prevented with vitamin E. There was no difference between wild type and Hp 2 mice with regard to renal hypertrophy in the absence of diabetes. However, in the presence of diabetes, Hp 2 mice demonstrated a significant increase in renal hypertrophy as compared to wild‐type mice. Conclusions These results support a direct linkage between diabetic vascular disease and the Hp genotype. These Hp‐modified mice may serve as a platform on which to test a variety of pharmacological agents in order to decrease diabetic vascular disease. Copyright © 2005 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom